Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142438 | 0.66 | PRMT5 (0.49) | — | |
| SCHEMBL21662217 | 0.64 | DGKA (0.43) | NLRP3 | |
| SCHEMBL10587627 | 0.63 | EHMT1 (0.71) | — | |
| SCHEMBL1669299 | 0.62 | EHMT1 (0.69) | — | |
| SCHEMBL5364744 | 0.62 | EHMT1 (0.69) | — | |
| SCHEMBL5561909 | 0.62 | EHMT1 (0.69) | — | |
| SCHEMBL6328713 | 0.61 | DGKA (0.43) | NLRP3 | |
| SCHEMBL21681151 | 0.60 | TLR4 (0.49) | — | |
| SCHEMBL20521198 | 0.60 | TLR4 (0.49) | — | |
| SCHEMBL10071463 | 0.59 | DGKA (0.52) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239665-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2 | GILEAD SCIENCES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885NLRP3 1317/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885NLRP3 1317/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | POLRMT 20/4885TMPRSS2 141/4885NLRP3 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.